TECH
Bio-Techne Corporation
$72.12
Stable Earnings Power
80%
P/Adj-EPS × Normalized Multiple
Strong
·
Conviction
Overvalued
Trading 344.1% above fair value
You pay
$72.12
Bear
$13.92
Fair
$16.24
Bull
$18.56
Bear
$13.92
-80.7%
$1.16 × 12x P/E
Fair
$16.24
-77.5%
$1.16 × 14x P/E
Bull
$18.56
-74.3%
$1.16 × 16x P/E
Adjust Assumptions
14.0x
1.16$
Key Value Driver
Normalized P/E multiple (14x base case)
Implied Market Multiple
62.2x
Analyst Consensus (External Reference)
Never blended into the bear/base/bull estimates above.
Average Target (26 analysts)
$65.78
Divergence from AlphaVal
75%
Summary
Applying a 14x P/E to adjusted EPS of $1.16, the base-case value is $16.24 per share.
Warnings
Wall Street's average price target is $65.78 (from 26 analysts). Our estimate is 75% below the consensus -- consider that gap carefully.
Key Risks
- Growth DCF inappropriate — terminal value assumptions dominate
- EV/EBITDA misleading for regulated businesses where capex is mandated
- Regulatory risk is a fat tail not visible in normal multiples